Management of Acute Limb Ischemia in Patients with Immune Thrombocytopenia

Immediate Stabilization and Anticoagulation

The American College of Radiology recommends starting therapeutic anticoagulation with unfractionated heparin immediately upon diagnosis of acute limb ischemia, even in the presence of thrombocytopenia, as the thrombotic risk outweighs bleeding risk in this life-threatening emergency 4
Obtain baseline labs including platelet count, PT/PTT, and assess for hypercoagulability markers (factor V Leiden, prothrombin C-20210a, anti-cardiolipin antibody, protein C/S, anti-thrombin III) 4

The American College of Hematology recommends administering IVIg 1 g/kg over 1-2 days as it has the most rapid onset of action (within 24 hours) for raising platelet counts 5, 1, 2, 3
Combine IVIg with high-dose corticosteroids (prednisone 1 mg/kg/day or methylprednisolone) to enhance IVIg response and prevent aseptic meningitis 5, 1
For Rh(D)-positive non-splenectomized patients, IV anti-D (50-75 μg/kg) is an alternative that may produce higher peak platelet counts 2, 3
Monitor platelet count every 6-12 hours during acute management 1

The American College of Radiology recommends CTA as the diagnostic test of choice to determine the exact level and nature of thrombosis and plan treatment strategy 4
For viable limbs with native vessel thrombosis where a guidewire can be passed, catheter-directed thrombolysis is preferred using alteplase, reteplase, or urokinase 4
Consider adding glycoprotein IIb/IIIa antagonist (abciximab) to reduce distal emboli during thrombolysis 4
US-assisted pharmacologic thrombolysis or mechanical thrombectomy (suction embolectomy, rheolytic therapy) may reduce infusion duration and are useful when thrombolysis is contraindicated 4
Surgical thrombectomy or bypass should be considered for patients with severe ischemia who cannot tolerate prolonged thrombolysis or when endovascular approaches fail 4

Administer platelet transfusions immediately before and during surgical or endovascular procedures in conjunction with continuous IVIg infusion to maintain hemostatic platelet counts 1, 2
Platelet transfusions every 30 minutes to 8 hours may be required during the procedure, though the effect is short-lived 1, 2
Coordinate closely with the blood bank before any transfusions 6

Do not use recombinant factor VIIa routinely: while it has been used in bleeding ITP patients, it carries significant thrombosis risk and should be reserved for life-threatening hemorrhage only 1, 2
Monitor for ITP treatment complications: IVIg can cause renal failure and thrombosis (rare but serious); corticosteroids increase infection risk 5
Distinguish ITP from TTP: if schistocytes are present on peripheral smear with MAHA, this represents TTP (not ITP) requiring immediate plasma exchange, not platelet transfusions 7

Continue therapeutic anticoagulation indefinitely after successful revascularization 4
Transition ITP management to second-line therapy (TPO-RAs or rituximab) if platelet count remains <30 × 10⁹/L after acute event resolution 8
Assess and treat any underlying atherosclerotic lesions to prevent recurrence 4